Park JG, et al. - The objective of this study is to compare the effectiveness of and mortality after lamivudine (LAM), tenofovir (TDF), and entecavir (ETV) treatment in patients with severe acute chronic hepatitis B (CHB) exacerbation. The current study showed that the LAM, ETV, and TDF selection are not associated with mortality and LT in patients with severe acute CHB exacerbation and hepatic decompensation. They also suggest that patients with ascites and MELD scores above 25 must be considered for LT, to decrease mortality.